Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1994 May 10;91(10):4353–4356. doi: 10.1073/pnas.91.10.4353

A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex.

M S Lidow 1, P S Goldman-Rakic 1
PMCID: PMC43783  PMID: 8183912

Abstract

The potencies of the major neuroleptics used in the treatment of schizophrenia, including haloperidol and remoxipride, correlate with their ability to bind D2-dopaminergic receptors in subcortical structures. On the other hand, the neuroleptic clozapine has a low affinity for these sites, and the pharmacological basis of its beneficial action is less clear. We have found that chronic treatment with clozapine, haloperidol, and remoxipride up-regulates D2 receptors in specific cortical areas of the rhesus monkey frontal, parietal, temporal, and occipital lobes. Of particular interest, all three neuroleptics down-regulated D1 receptors in prefrontal and temporal association regions--the two areas most often associated with schizophrenia. This latter finding raises the possibility that down-regulation of D1 receptors in prefrontal and temporal cortex may be an important component of the therapeutic response to neuroleptic drugs. Further, the common effects of three neuroleptics with different pharmacological profiles in the cerebral cortex is consistent with the idea that this structure is a major therapeutic target in the treatment of schizophrenia.

Full text

PDF
4353

Images in this article

4354Image
on p.4354
4355Image
on p.4355

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bacopoulos N. C., Spokes E. G., Bird E. D., Roth R. H. Antipsychotic drug action in schizophrenic patients: effect on cortical dopamine metabolism after long-term treatment. Science. 1979 Sep 28;205(4413):1405–1407. doi: 10.1126/science.38504. [DOI] [PubMed] [Google Scholar]
  2. Bannon M. J., Roth R. H. Pharmacology of mesocortical dopamine neurons. Pharmacol Rev. 1983 Mar;35(1):53–68. [PubMed] [Google Scholar]
  3. Creese I., Burt D. R., Snyder S. H. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science. 1976 Apr 30;192(4238):481–483. doi: 10.1126/science.3854. [DOI] [PubMed] [Google Scholar]
  4. Creese I., Hess E. J. Biochemical characteristics of D1 dopamine receptors: relationship to behavior and schizophrenia. Clin Neuropharmacol. 1986;9 (Suppl 4):14–16. [PubMed] [Google Scholar]
  5. Davis K. L., Kahn R. S., Ko G., Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry. 1991 Nov;148(11):1474–1486. doi: 10.1176/ajp.148.11.1474. [DOI] [PubMed] [Google Scholar]
  6. Essig E. C., Kilpatrick I. C. Influence of acute and chronic haloperidol treatment on dopamine metabolism in the rat caudate-putamen, prefrontal cortex and amygdala. Psychopharmacology (Berl) 1991;104(2):194–200. doi: 10.1007/BF02244178. [DOI] [PubMed] [Google Scholar]
  7. Gerfen C. R., Engber T. M., Mahan L. C., Susel Z., Chase T. N., Monsma F. J., Jr, Sibley D. R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 1990 Dec 7;250(4986):1429–1432. doi: 10.1126/science.2147780. [DOI] [PubMed] [Google Scholar]
  8. Grace A. A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience. 1991;41(1):1–24. doi: 10.1016/0306-4522(91)90196-u. [DOI] [PubMed] [Google Scholar]
  9. Hall H., Sällemark M. Effects of chronic neuroleptic treatment on agonist affinity states of the dopamine-D2 receptor in the rat brain. Pharmacol Toxicol. 1987 May;60(5):359–363. doi: 10.1111/j.1600-0773.1987.tb01527.x. [DOI] [PubMed] [Google Scholar]
  10. Janowsky A., Neve K. A., Kinzie J. M., Taylor B., de Paulis T., Belknap J. K. Extrastriatal dopamine D2 receptors: distribution, pharmacological characterization and region-specific regulation by clozapine. J Pharmacol Exp Ther. 1992 Jun;261(3):1282–1290. [PubMed] [Google Scholar]
  11. Laruelle M., Jaskiw G. E., Lipska B. K., Kolachana B., Casanova M. F., Kleinman J. E., Weinberger D. R. D1 and D2 receptor modulation in rat striatum and nucleus accumbens after subchronic and chronic haloperidol treatment. Brain Res. 1992 Mar 13;575(1):47–56. doi: 10.1016/0006-8993(92)90421-5. [DOI] [PubMed] [Google Scholar]
  12. Lidow M. S., Goldman-Rakic P. S., Gallager D. W., Rakic P. Distribution of dopaminergic receptors in the primate cerebral cortex: quantitative autoradiographic analysis using [3H]raclopride, [3H]spiperone and [3H]SCH23390. Neuroscience. 1991;40(3):657–671. doi: 10.1016/0306-4522(91)90003-7. [DOI] [PubMed] [Google Scholar]
  13. Lidow M. S., Goldman-Rakic P. S., Rakic P., Innis R. B. Dopamine D2 receptors in the cerebral cortex: distribution and pharmacological characterization with [3H]raclopride. Proc Natl Acad Sci U S A. 1989 Aug;86(16):6412–6416. doi: 10.1073/pnas.86.16.6412. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Malmberg A., Jackson D. M., Eriksson A., Mohell N. Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. Mol Pharmacol. 1993 May;43(5):749–754. [PubMed] [Google Scholar]
  15. Meador-Woodruff J. H., Mansour A., Healy D. J., Kuehn R., Zhou Q. Y., Bunzow J. R., Akil H., Civelli O., Watson S. J., Jr Comparison of the distributions of D1 and D2 dopamine receptor mRNAs in rat brain. Neuropsychopharmacology. 1991 Dec;5(4):231–242. [PubMed] [Google Scholar]
  16. Memo M., Pizzi M., Missale C., Carruba M. O., Spano P. F. Modification of the function of D1 and D2 dopamine receptors in striatum and nucleus accumbens of rats chronically treated with haloperidol. Neuropharmacology. 1987 May;26(5):477–480. doi: 10.1016/0028-3908(87)90030-x. [DOI] [PubMed] [Google Scholar]
  17. O'Dell S. J., La Hoste G. J., Widmark C. B., Shapiro R. M., Potkin S. G., Marshall J. F. Chronic treatment with clozapine or haloperidol differentially regulates dopamine and serotonin receptors in rat brain. Synapse. 1990;6(2):146–153. doi: 10.1002/syn.890060205. [DOI] [PubMed] [Google Scholar]
  18. O'Malley K. L., Mack K. J., Gandelman K. Y., Todd R. D. Organization and expression of the rat D2A receptor gene: identification of alternative transcripts and a variant donor splice site. Biochemistry. 1990 Feb 13;29(6):1367–1371. doi: 10.1021/bi00458a003. [DOI] [PubMed] [Google Scholar]
  19. Pflug B., Bartels M., Bauer H., Bunse J., Gallhofer B., Haas S., Kanzow W. T., Klieser E., Küfferle B., Stein D. A double-blind multicentre study comparing remoxipride, controlled release formulation, with haloperidol in schizophrenia. Acta Psychiatr Scand Suppl. 1990;358:142–146. doi: 10.1111/j.1600-0447.1990.tb05307.x. [DOI] [PubMed] [Google Scholar]
  20. Rupniak N. M., Hall M. D., Mann S., Fleminger S., Kilpatrick G., Jenner P., Marsden C. D. Chronic treatment with clozapine, unlike haloperidol, does not induce changes in striatal D-2 receptor function in the rat. Biochem Pharmacol. 1985 Aug 1;34(15):2755–2763. doi: 10.1016/0006-2952(85)90577-5. [DOI] [PubMed] [Google Scholar]
  21. Scatton B., Glowinski J., Julou L. Dopamine metabolism in the mesolimbic and mesocortical dopaminergic systems after single or repeated administrations of neuroleptics. Brain Res. 1976 Jun 4;109(1):184–189. doi: 10.1016/0006-8993(76)90391-7. [DOI] [PubMed] [Google Scholar]
  22. See R. E., Toga A. W., Ellison G. Autoradiographic analysis of regional alterations in brain receptors following chronic administration and withdrawal of typical and atypical neuroleptics in rats. J Neural Transm Gen Sect. 1990;82(2):93–109. doi: 10.1007/BF01245166. [DOI] [PubMed] [Google Scholar]
  23. Seeman P. Atypical neuroleptics: role of multiple receptors, endogenous dopamine, and receptor linkage. Acta Psychiatr Scand Suppl. 1990;358:14–20. doi: 10.1111/j.1600-0447.1990.tb05280.x. [DOI] [PubMed] [Google Scholar]
  24. Seeman P., Chau-Wong M., Tedesco J., Wong K. Brain receptors for antipsychotic drugs and dopamine: direct binding assays. Proc Natl Acad Sci U S A. 1975 Nov;72(11):4376–4380. doi: 10.1073/pnas.72.11.4376. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Seeman P., Niznik H. B., Guan H. C., Booth G., Ulpian C. Link between D1 and D2 dopamine receptors is reduced in schizophrenia and Huntington diseased brain. Proc Natl Acad Sci U S A. 1989 Dec;86(24):10156–10160. doi: 10.1073/pnas.86.24.10156. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Shenton M. E., Kikinis R., Jolesz F. A., Pollak S. D., LeMay M., Wible C. G., Hokama H., Martin J., Metcalf D., Coleman M. Abnormalities of the left temporal lobe and thought disorder in schizophrenia. A quantitative magnetic resonance imaging study. N Engl J Med. 1992 Aug 27;327(9):604–612. doi: 10.1056/NEJM199208273270905. [DOI] [PubMed] [Google Scholar]
  27. Strange P. G. D1/D2 dopamine receptor interaction at the biochemical level. Trends Pharmacol Sci. 1991 Feb;12(2):48–49. doi: 10.1016/0165-6147(91)90494-d. [DOI] [PubMed] [Google Scholar]
  28. Van Tol H. H., Bunzow J. R., Guan H. C., Sunahara R. K., Seeman P., Niznik H. B., Civelli O. Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature. 1991 Apr 18;350(6319):610–614. doi: 10.1038/350610a0. [DOI] [PubMed] [Google Scholar]
  29. Weinberger D. R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry. 1987 Jul;44(7):660–669. doi: 10.1001/archpsyc.1987.01800190080012. [DOI] [PubMed] [Google Scholar]
  30. Weinberger D. R. Schizophrenia and the frontal lobe. Trends Neurosci. 1988 Aug;11(8):367–370. doi: 10.1016/0166-2236(88)90060-4. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES